Current Report Filing (8-k)
03 December 2021 - 11:01PM
Edgar (US Regulatory)
0001178879
false
0001178879
2021-12-03
2021-12-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT TO
SECTION
13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): December 3, 2021
AMICUS THERAPEUTICS, INC.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
|
|
001-33497
|
|
71-0869350
|
(State
or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification No.)
|
3675 Market Street,
Philadelphia, PA 19104
(Address of Principal
Executive Offices, and Zip Code)
215-921-7600
Registrant’s
Telephone Number, Including Area Code
(Former Name or Former Address, if Changed Since
Last Report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant
to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common Stock Par Value $0.01
|
|
FOLD
|
|
NASDAQ
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR §240.12b-2). Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01 – Other Events
On December 3, 2021, Amicus Therapeutics, Inc. (the “Company”)
issued a press release announcing that the European Medicines Agency validated the Marketing Authorization Applications for AT-GAA, the
Company’s investigational two-component therapy for the treatment of Pompe disease. A copy of this press release is attached hereto
as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits:
Signature Page
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
AMICUS THERAPEUTICS, INC.
|
|
|
Date: December 3, 2021
|
By:
|
/s/ Ellen S. Rosenberg
|
|
Name: Ellen S. Rosenberg
|
|
Title: Chief Legal Officer and Corporate Secretary
|
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Apr 2023 to Apr 2024